PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

Breast Cancer Clinical Trial

Official title:

Pre-Surgical Window Pilot Investigation of the Effect of PARP Inhibition on the Cellular and Molecular Changes in Primary Ovarian and Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04041128
• Other study ID #: STU-2019-0769
• Status: Completed
• Phase: Early Phase 1
• Start date: July 23, 2019
• Est. completion date: June 15, 2021

Study information

• Verified date: March 2023
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study involves surgery for cytoreduction or laparoscopy to determine if you are a candidate for tumor debulking or a tissue biopsy. Following this surgery you will receive chemotherapy. This study will administer 7 days of treatment with a targeted therapy called Lynparza. Lynparza and/or other PARP inhibitors have been FDA approved for the treatment of ovarian and breast cancer. Tissue biopsy will be done before a 7 day course of Lynparza in order to correlate molecular changes to response to treatment. Participation in this trial will require an additional tumor biopsy which will occur either before or after treatment of Lynparza.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: June 15, 2021
• Est. primary completion date: June 15, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• All patients must have cytology/ biopsy proven diagnosis of a mullerian carcinoma, high clinical index of suspicion for ovarian cancer OR triple negative, BRCA mutated breast cancer.

• Patients may not have received prior treatment for breast or ovarian cancer.

• All patients must be of at least 18 years of age.

• ECOG Performance status must be 0,1 or 2.

• Patients must not have received a prior PARP inhibitor

• Adequate organ and marrow function as defined below:

• absolute neutrophil count >/= 1500/mcL

• Platelets > /= 100,000 /mcl

• Hemoglobin >/= 8 g/dl

• Total bilirubin </= 1.5 x the institutional ULN

• AST, ALT </= 3 x the institutional ULN

• Creatinine </= the institutional ULN

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

• A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

• Has not undergone a hysterectomy or bilateral oophorectomy; or

• Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

• Patients must be able to swallow and retain oral medications.

• Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

• Chemotherapy, radiotherapy, or other cancer therapy within 4 weeks prior to starting study treatment. Subjects must have recovered from prior treatment-related to toxicities to grade 1 or baseline (excluding alopecia and clinically stable toxicities requiring ongoing medical management, such as hypothyroidism from prior immune checkpoint inhibitor treatment).

• Subjects may not be receiving any other investigational agents for the treatment of the cancer under study.

• Brain metastases

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Lynparza or other agents used in study.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.

• Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Ovarian Cancer

Intervention

Drug:
• Lynparza
Lynparza taken orally at a dose of 300mg twice daily for 7 days

Locations

Country	Name	City	State
United States	University of Texas Southwestern Medical Center	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure DNA damage response to PARP inhibition	Paired t-test or Wilcoxon signed-rank test will be used to examine if there is a significant change in ADP ribosylated proteome, DNA damage, apoptosis and change in RAD 51 foci between pre-and post-treatment cancer specimens.	Following 7 days of Lynparza
Primary	Characterize changes in ADP ribosylation to PARP inhibition	Spearman rank correlation will be computed to estimate the correlation between the changes in ADP ribosylation with the response (measured by immunohistochemistry: ?H2AX and caspase -3 cleavage)	Following 7 days of Lynparza
Primary	Correlate DNA damage response to ADP ribosylated proteome	Paired t-test or Wilcoxon signed-rank test will be used to examine if there is a significant change in ADP ribosylated proteome, DNA damage, apoptosis and change in RAD 51 foci between pre-and post-treatment cancer specimens	Following 7 days of Lynparza